Last reviewed · How we verify
NCT06569602
Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU)
trial testing Transcatheter Tricuspid Valve Replacement in Tricuspid Valve Regurgitation in 500 participants. Currently enrolling.
30 September 2030
Quick facts
| Lead sponsor | Edwards Lifesciences |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 October 2024 |
| Primary completion | 30 September 2030 |
| Estimated completion | 30 September 2033 |
| Sites | 2 locations across Switzerland, Germany |
Drugs / interventions tested
- Transcatheter Tricuspid Valve Replacement
Conditions studied
- Tricuspid Valve Regurgitation — all drugs for Tricuspid Valve Regurgitation →
- Heart Valve Diseases — all drugs for Heart Valve Diseases →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
Sponsor
Edwards Lifesciences — full company profile →
Who can join
Eligibility, any sex, with Tricuspid Valve Regurgitation or Heart Valve Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, single-arm, multi-center, real-world study of an the Edwards EVOQUE system.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06569602
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Transcatheter Tricuspid Valve Replacement
Trials testing the same drug.
- NCT06611579 — Clinical Study of the inQB8 TTVR System · NA · recruiting
- NCT06581471 — The TRICURE EU Pivotal Study · NA · recruiting
- NCT04905017 — Trisol System EFS Study · NA · recruiting
- NCT04221490 — 2019-06 TRISCEND Study · NA · active not recruiting
Other recruiting trials for Tricuspid Valve Regurgitation
Currently open trials in the same condition.
- NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting
- NCT06611579 — Clinical Study of the inQB8 TTVR System · NA · recruiting
- NCT06581471 — The TRICURE EU Pivotal Study · NA · recruiting
- NCT07342036 — Prospective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion · recruiting
- NCT05760989 — TRISCEND JAPAN Study · NA · active not recruiting
Other Edwards Lifesciences trials
Trials by the same sponsor.
- NCT07317648 — ClearSight NextGen1 Study · NA · completed
- NCT06833476 — TTVR STRONG Under Coverage With Evidence Development (CED) Study · recruiting
- NCT06834516 — ClearSight Baby Cuff · completed
- NCT05957406 — SMART TRENDS Study · NA · completed
- NCT05686317 — ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06569602 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Edwards Lifesciences
- Last refreshed: 31 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06569602.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing